A 24-week double blind treatment and 24-week follow up, randomized, multi-center, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass and physical performance in patients after surgical treatment of hip fracture
1st June 2017 - ongoing
Status: Active
Specialism: Liver.
Team:
PI: Opinder Sahota
People
Photo | Name | Bio |
---|
Publications
Title |
---|
Grants
Title | Amount |
---|